Capabilities

Divestiture of Elidel® to Meda AB

Novartis

Our attorneys represented Novartis in an agreement to sell to Meda AB the global rights to manufacture, market and commercialize Elidel® (pimecrolimus) Cream 1%, a medicine to treat mild to moderate atopic dermatitis.  

Email Disclaimer